GUGLIELMETTI SIMONE DOMENICO (IT)
FIORE WALTER (IT)
| AMENDED CLAIMS received by the International Bureau on 15 November 2023 (15.11.2023) 1. A bacteria strain belonging to the species Lacticaseibacillus paracasei deposited as Lacticaseibacillus paracasei DG 1-1572 DSM 34154 for use in a method of treating dysbiosis of the intestinal microbiota of subjects with IBS, wherein said subjects are classified as non-constipated. 2. The bacteria for use according to claim 1, wherein said subjects with IBS have elevated levels of Collinsella aerofaciens, Bacteroides plebeius, Dorea spp., Ruminococcus bromii, Ruminococcus spp., Blautia spp. 3. The bacteria for use according to claim 1 or 2, wherein said elevated levels of Collinsella aerofaciens, Bacteroides plebeius, Dorea spp., Ruminococcus bromii, Ruminococcus spp., Blautia spp. are present in the feces of subjects with IBS in need. 4. The bacteria for use according to anyone claims 1-3, wherein said bacteria is administered orally, preferably in the form human supplement Enterolactis® Plus capsules. 5. The bacteria for use according to anyone claims 1-4, wherein said human supplement is preferably administered twice daily, for a period of time preferably from 4 to 24 weeks, more preferably from 8 to 12 weeks. 6. The bacteria for use according to anyone of claims 1-5, wherein each of said capsules contains from lxlO6 a lxlO12, more preferably from lxlO8 to lxlO10, even more preferably from 10xl09 to 50xl09 CFU/capsule. 7. The bacteria for use according to anyone of claims 1-6, wherein said bacteria is present in each of said capsules in solid form, preferably powder, dry or lyophilized. 8. The bacteria for use according to anyone claims 1-7, wherein the daily dose may comprise from 1 to 4 capsules, preferably from 2 to 3 capsules/day. 9. The bacteria for use according to anyone of claims 1-8, wherein said bacteria is for use in a method for the treatment of abdominal symptoms in non-constipated IBS patients. AMENDED SHEET (ARTICLE 19) |